BAFNAPH

Bafna Pharmaceuticals Share Price

 

 

Start SIP in BAFNAPH

Start SIP

Performance

  • Low
  • ₹127
  • High
  • ₹133
  • 52 Week Low
  • ₹69
  • 52 Week High
  • ₹202
  • Open Price₹129
  • Previous Close₹130
  • Volume832
  • 50 DMA₹148.40
  • 100 DMA₹140.29
  • 200 DMA₹123.59

Investment Returns

  • Over 1 Month -12.36%
  • Over 3 Month -18.22%
  • Over 6 Month + 53.05%
  • Over 1 Year + 54.03%

Smart Investing Starts Here Start SIP with Bafna Pharmaceuticals for Steady Growth!

Invest Now

Bafna Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 34.4
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 302
  • P/B Ratio
  • 3.3
  • Average True Range
  • 5.97
  • EPS
  • 4.47
  • Dividend Yield
  • 0
  • MACD Signal
  • -2.3
  • RSI
  • 32.73
  • MFI
  • 42.52

Bafna Pharmaceuticals Financials

Bafna Pharmaceuticals Technicals

EMA & SMA

Current Price
₹127.60
-2.39 (-1.84%)
pointer
  • Bearish Moving Average 13
  • Bullish Moving Average 3
  • 20 Day
  • ₹145.76
  • 50 Day
  • ₹148.40
  • 100 Day
  • ₹140.29
  • 200 Day
  • ₹123.59

Resistance and Support

129.71 Pivot Speed
  • R3 138.88
  • R2 135.73
  • R1 132.86
  • S1 126.84
  • S2 123.69
  • S3 120.82

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Bafna Pharmaceuticals has an operating revenue of Rs. 142.34 Cr. on a trailing 12-month basis. An annual revenue de-growth of -5% needs improvement, Pre-tax margin of 3% needs improvement, ROE of 4% is fair but needs improvement. The company has a reasonable debt to equity of 17%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 17% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 48 which is a POOR score indicating inconsistency in earnings, a RS Rating of 90 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 56 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Bafna Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-11 Quarterly Results
2025-08-12 Quarterly Results
2025-05-26 Audited Results
2025-02-06 Quarterly Results
2024-11-11 Quarterly Results

Bafna Pharmaceuticals F&O

Bafna Pharmaceuticals Shareholding Pattern

75%
9.34%
12.04%
3.62%

Bafna Pharmaceuticals FAQs

Bafna Pharmaceuticals share price is ₹127 As on 14 January, 2026 | 12:25

The Market Cap of Bafna Pharmaceuticals is ₹301.9 Cr As on 14 January, 2026 | 12:25

The P/E ratio of Bafna Pharmaceuticals is 34.4 As on 14 January, 2026 | 12:25

The PB ratio of Bafna Pharmaceuticals is 3.3 As on 14 January, 2026 | 12:25

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23